Digi Expands IoT Solutions for Medical, Smart Energy and Industrial Sectors with Newest Addition to the MP1 Family of System-On-Modules
13.3.2023 11:00:00 EET | Business Wire | Press release
Digi International (NASDAQ: DGII, www.digi.com), a leading global provider of Internet of Things (IoT) solutions, connectivity products and services, and an ST Authorized Partner, today unveiled Digi ConnectCore® MP13, the newest member of its Digi ConnectCore® MP1 family of system-on-modules (SOMs) designed for longevity, scalability and demanding product lifecycles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230313005132/en/
Digi ConnectCore MP13 System-on-Module unveiled at Embedded World 2023 (Graphic: Business Wire)
A compact, wireless and secure system-on-module based on the STMicroelectronics STM32MP133C MPU, Digi ConnectCore MP13 is among the industry’s smallest SOMs with pre-certified Wi-Fi 5 and Bluetooth® 5.2. This solution delivers cost-effective, flexible and reliable connectivity for original equipment manufacturers (OEMs) looking to reduce risk and product development efforts, while accelerating overall time to market of applications for the medical, smart energy and industrial sectors.
Complete with embedded security framework, Digi TrustFence®, and Digi Embedded Yocto Linux® software support, Digi ConnectCore MP13 SOMs eliminate implementation barriers and offer exceptional design flexibility for both complex and simple applications thanks to the unique and compact Digi SMTplus® surface-mount form factor (29x29 mm) — making them ideal for medical devices, industrial gateways, environmental test equipment, renewable-energy controllers and EV charging stations.
“We are delighted to expand the Digi ConnectCore MP1 family of SOMs and continue our commitment to providing off-the-shelf, wireless-enabled solutions suitable for a broad range of applications,” said Andreas Burghart, Senior Product Manager at Digi. “Designed for longevity, scalability and demanding 10+ year product lifecycles, Digi ConnectCore MP13 is a well-suited addition to our complete ecosystem of hardware, software and services that help manufacturers successfully develop and maintain connected products.”
Digi ConnectCore MP1 SOMs are distinct from other SOMs in that they offer comprehensive, fully-integrated solutions, which include a range of development tools, design support, wireless connectivity options, software and security features. These solutions include access to Digi ConnectCore Cloud Services and Digi ConnectCore Security Services, which aid in streamlining deployment, device management and ongoing maintenance across the product's entire lifecycle.
Digi ConnectCore MP13 Features
- STM32MP13x, single Cortex-A7 @ 650 MHz
- Pre-certified Wi-Fi 5 802.11a/b/g/n/ac + Bluetooth 5.2 (including DLE) option
- Up to 1 GB SLC NAND flash, up to 1 GB DDR3
- Unique ultra-low power and wake-up state management
- Dual 10/100/1000 Ethernet connectivity
- Fully validated embedded Linux software platform (Digi Embedded Yocto)
- Digi TrustFence® embedded security framework — ready-to-use security features
- Off-the-shelf development board and low-cost gateway reference design
- Industrial reliability and operating temperature with leading hardware warranty
“With the launch of Digi ConnectCore MP13, Digi has created pin-compatible family of SOMs to support the ST Microelectronics STM32MP1 microprocessors,” said Dan Kobylarz, Senior Director of Engineering, OEM Solutions Group at Digi. “The ConnectCore MP13 is ideal for the rapid development of cost-effective gateways for Smart City and Energy applications, while the ConnectCore MP15 supports connected devices with HMI requirements. With the ConnectCore MP1 SOM family, a customer gets the best of both worlds.”
For more information, visit https://www.digi.com/products/embedded-systems/digi-connectcore/system-on-modules/digi-connectcore-mp1.
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. It helps companies create next-generation connected products and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped customers connect more than 100 million things and counting. For more information, visit https://www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230313005132/en/
Contact information
Peter Ramsay
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release
Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release
For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom